

1 **FTThe Effects of Curcumin Supplementation on Body Weight, Body Mass Index, and Waist**
2 **Circumference in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of**
3 **Randomized Controlled Trials**

4
5 Noorbakhsh Alivand¹, Soleyman Alivand², Seyed jalil masoumi³, Sahar foshati⁴, Ebrahim Abbasi^{5*}
6
7

8 ¹Department of Nutrition, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

9 ²Department of Biostatistical and Epidemiology, School of health, Isfahan University of Medical
10 Sciences, Isfahan, Iran.

11 ³Nutrition research center, school of nutrition and food sciences, Nutrition research center, school of
12 nutrition and food sciences,

13 ⁴Department of Nutrition, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

14 ⁵Department of Medical Entomology and Vector Control, School of Health, Shiraz University of Medical
15 Sciences, Shiraz, Iran.

16
17 Correspondence should be sent to E. Abbasi (<https://orcid.org/000-993-1861-5321>) at
18 abbasie.ebrahim@gmail.com or e_abbasie@sums.ac.ir
19
20

21 **Abstract**

22 The study investigates the effects of curcumin on obesity and its related factors in diabetic patients, given
23 that obesity can lead to insulin resistance and complicate diabetes management. An analysis of nine
24 randomized controlled trials (RCTs) involving 699 participants was conducted to evaluate curcumin's
25 impact on body weight (BW), body mass index (BMI), and waist circumference (WC). The results
26 indicated a significant reduction in BW (WMD: -1.65 kg), BMI (WMD: -0.69 kg/m²), and WC (WMD: -
27 0.93 cm) with curcumin consumption compared to controls. Higher doses of curcumin (>1000 mg/day)
28 were notably more effective in reducing BW, BMI, and WC than lower doses. The study concludes that
29 curcumin supplementation effectively reduces BW, BMI, and WC in diabetic patients, especially at
30 higher doses, and suggests the need for further studies to explore these benefits.

31 **Keywords:** Curcumin, Body Mass Index, Body Weight, Waist Circumference, Obesity, Diabetes
32
33
34
35

36 **Introduction**

37 Diabetes mellitus is a group of metabolic diseases involving hyperglycemia due to defects in insulin
38 secretion, action, or both or insulin resistance in skeletal muscle, liver, and adipose tissues, with a failure
39 of B-cell compensation and a relative insulin deficiency[1].

40 Recently, the incidence of diabetes has increased, and it is expected that the prevalence of type 2 diabetes
41 among adults will increase from 285 million patients in 2010 to 438 million patients in 2030. More than
42 60% of diabetic patients live in Asia, and there are more than 4 million type 2 diabetic patients in Iran[2].
43 Besides, almost 90% of T2DM patients are overweight or obese[3].

44 Obesity, in particular in the form of abdominal adiposity, is known to be associated with increased
45 morbidity and mortality[4]. Diabetes is an obesity-associated disease linked to insulin resistance and
46 hyperglycemia[5]. Recent research has shown that obesity affects more than 600 million people
47 worldwide[6]. Additionally, if scientists do not take immediate action, many people will experience
48 obesity-related disorders, such as type 2 diabetes[2]. Obesity and overweight are two major risk factors
49 for diabetes and its complications. Investigations indicate that almost 90% of diabetic patients are
50 overweight. Obesity can affect the metabolism in the body by causing insulin resistance and reducing
51 insulin secretion[7]. Therefore, the management of obesity has been strongly recommended to control
52 diabetes and its complications[3].

53 Various courses of action, including surgical approaches, several drugs, and lifestyle interventions, have
54 been recommended for weight management; however, the effectiveness of these approaches is under
55 discussion[8]. Weight reduction resulted in a greater control of T2DM[3]. Lifestyle changes, i.e.,
56 supplementation and exercise, are among the complementary treatment approaches in patients suffering
57 from T2DM .(Diabetes Mellitus 2Type) Curcumin is one of the supplements with positive effects noticed
58 in weight control[9, 10].

59 Curcumin is the most important component of turmeric (*Curcuma longa*) and is yellow. It is commonly
60 used as a food additive in Asian countries[11]. It is also deemed responsible for many medical properties
61 of turmeric. Curcumin has low toxicity and performs various pharmacological functions, including
62 antioxidant, anti-inflammatory, anti-microbial, and anti-carcinogenic effects[6, 12, 13]. In some clinical
63 trials, the desirable effects of curcumin have been shown to be a therapeutic agent for the treatment of
64 diabetes and complications of high blood glucose[6].

65 Moreover, several studies reported conflicting effects of curcumin consumption on body weight and
66 composition. Some clinical trials proposed a significant effect of curcumin intake on indicators of body
67 composition[6, 14-16]. On the contrary, others reported no significant effect of curcumin intake on body
68 weight (BW) or body mass index (BMI)[3, 17, 18]. However, despite various studies conducted on the
69 effect of curcumin intake on body composition in patients with type 2 diabetes, no prior study has

70 examined BW, BMI, and WC solely in diabetic patients. Thus, the current study was done to perform a
71 comprehensive systematic review and meta-analysis of published randomized controlled trials (RCTs) to
72 independently evaluate the effect of curcumin supplementation on body weight (BW), body mass index
73 (BMI), and waist circumference (WC) in patients with type 2 diabetes.

74 **Materials and Methods**

75 The design of this systematic review and meta-analysis has been prepared according to the guidelines of
76 the **2020** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, **2020**)
77 statement[19]. Furthermore, reports of included and excluded primary studies in the different stages of the
78 current systematic review have been presented using the PRISMA flow chart.

79 **Search strategy**

80 Our meta-analysis was designed according to the guidelines of the PRISMA statement[19]. PubMed,
81 Scopus, and ISI, Web of Sciences databases were searched for English-language reports of relevant RCTs
82 published till January 2024 for related published articles evaluating the effects of curcumin
83 supplementation on body weight, body mass index, and waist circumference. The following MeSH terms
84 and related keywords were searched: "Curcumin "OR "Curcuminoid" OR "Curcuma" OR "Turmeric" OR
85 "Tumeric" OR "Curcuma longa "OR "C. longa" OR "Curcumin longa L." Details of our search strategy
86 are shown in Appendix S1. The search was not limited to the English language or human subjects.
87 Moreover, we hand-searched the reference list of included articles, related reviews, and meta-analyses.
88 PubMed's 'My NCBI' (National Centre for Biotechnology Information) email alert service was also
89 created to identify new articles that may be published after our search.

90 **Study selection**

91 Two investigators (N.AL and S.A) reviewed the titles and abstracts of all identified studies to ascertain
92 whether these studies are eligible for this meta-analysis based on our inclusion criteria. Discrepancies
93 were resolved by discussion with S.F. Studies were chosen for analysis according to the following
94 inclusion criteria: 1- the study was a placebo-controlled trial with either a parallel or crossover design; 2-
95 conducted in patients with type 2 diabetes; 3- the effects of curcumin on body weight, body mass index
96 and waist circumference could be extracted from the article (adequate information on body indices with
97 standard deviations (SDs), standard errors (SEs), or 95% CI, at baseline and the end of follow-up in
98 intervention and control group); 4- the studies with an appropriate controlled design, i.e., the only
99 difference between the control and intervention groups was curcumin; and 5- having an intervention
100 duration of at least four weeks. Studies were excluded if 1- we could not extract the net effect of
101 curcumin; 2- curcumin supplementation duration was < 4 weeks; and 3- non-RCT studies. Furthermore,
102 studies with animal, case-control, cross-sectional, or cohort designs, lacking necessary data for extraction,

103 and trials without appropriate controlled design, i.e., those articles using curcumin in combination with
104 other supplements, were excluded from this meta-analysis.

105

106 **2.3. Data extraction**

107 The following information was extracted from each of the eligible RCTs by two independent authors
108 (N.AL and F.S): first author's name, study location, year of publication, the sample size in each group,
109 type, and dose of intervention and placebo, duration of the intervention, study design (crossover or
110 parallel), patient's status and other information including age, gender, and baseline BMI. We also
111 extracted the mean and SD values of body parameters at the study baseline and end of the study. If the
112 data were reported at multiple measurements, only the values at the end of trials were used. In the studies
113 that used only one specific curcumin dose, the analysis included the dose.

114 **2.4. Quality assessment**

115 The risk of bias tool was applied using criteria outlined in the Cochrane Handbook for Systematic
116 Reviews of Interventions to assess methodological quality[20]. Two independent reviewers (N.AL and
117 FS) investigated the following criteria for each included study: random sequence generation, allocation
118 concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete
119 outcome data, selective outcome reporting, and other potential sources of biases. Any disagreement in the
120 quality assessment process was resolved through discussion and consultation with a third researcher
121 (S.F.).

122 **Quantitative data synthesis and statistical analysis**

123 We evaluated the influence of curcumin supplementation on change in the following outcomes: (I) body
124 weight (kg), (II) BMI (kg /m²), and (III) WC (cm). Effect sizes for the meta-analysis were defined as
125 weighted mean difference (WMD; value at the end of the trial minus the value at baseline) and 95%
126 CI[21]. In the event of no reported SD of the mean difference, it was calculated as follows:

$$127 \text{SD} \sqrt{[(= \text{SD pretreatment})^2 + (\text{SD posttreatment})^2]} - [(2R \times$$

128 $(\text{SD pretreatment} \times \text{SD posttreatment})]$

129 In which a correlation coefficient of 0.5 was assumed as this R-value is a conservative estimate between 0
130 and 1[22]. When SE was reported instead of SD, we converted SE to SD for analyses: $\text{SD} = \text{SE} \times \sqrt{n}$,
131 where n is the number of participants in each group. If interested outcomes were reported as median and
132 range, all mean and SD values were estimated using the method described by Hozo et al[23]. Plot
133 digitizer software was used to extract data only when the outcome variable was presented in graphic form.
134 Pre-defined subgroup analyses were performed on supplementation duration and supplement dosage.

135 Random-effects meta-regression analysis was performed using an unrestricted maximum likelihood
136 method to explore the association between changes in body weight, body mass index, duration, and dose
137 of curcumin supplementation. Statistical heterogeneity between studies was also evaluated using
138 Cochran's Q-test (significance set at $p < 0.1$) and I^2 ($\geq 50\%$ assumed to indicate substantial heterogeneity
139 among studies). In the presence of heterogeneity, the pooled effect size was calculated using a random-
140 effects model; otherwise, we applied a fixed-effects model. Sensitivity analysis was used to explore the
141 extent to which inferences might depend on a particular study using the leave-one-out method (i.e.,
142 removing a single trial at a time and repeating the analyses[24]). Publication bias was assessed using
143 funnel plots, Begg's rank correlation, and Egger's weighted regression tests. In the event of publication
144 bias, the Duval and Tweedie 'trim and fill' and 'fail-safe N' methods were utilized[25]. All statistical
145 analyses were performed using Comprehensive Meta-Analysis (CMA) V3 software with a significance
146 level of $p < 0.05$.

147 **Results**

148 **Selection of trials**

149 The explicit research screening process is shown in Figure 1. The preliminary and additional database
150 retrieval yielded 2925 records, with 459 articles excluded due to duplicated records and 274 articles due
151 to review records. A total of 2110 items were eliminated after reading the titles and abstracts following
152 the inclusion and exclusion criteria. After reading the full texts of 82 studies, seventy-three studies were
153 excluded for the following reasons: duplicate report ($n = 3$), not randomized placebo-controlled studies (n
154 $= 5$), not providing enough information ($n = 38$), animal study ($n = 3$), vitro study ($n = 3$), review study (n
155 $= 2$), no anthropometric measurements performed ($n = 17$) and use of curcumin in combination with other
156 components without an appropriate control group ($n = 2$). Nine eligible RCTs were included in the meta-
157 analyses[1-3, 6, 10, 13, 26-28]. Of these, six articles reported the effects of curcumin on BW, eight
158 articles on BMI, and three on WC.

159 **Characteristics of the included studies**

160 Study characteristics of the 9 eligible articles are presented in Table 1. Data were pooled from these
161 studies, and the sample size ranged from 21 to 213. Overall, 1,088 participants were randomly assigned in
162 these trials, and 699 participants (64.24%) completed the studies. The mean age of the participants ranged
163 from 43 to 62.5 years. One of the nine trials was performed exclusively on women [10]. The eight
164 remaining trials included both sexes. Eligible studies were published between 2014 and 2021, most of
165 which were conducted in Iran. The remaining studies were conducted in Thailand and Brazil. Seven
166 treatment arms used curcumin for the intervention. Cooked rice, Polysorbate capsules, placebo capsules,
167 maltodextrin, placebo capsules containing starch, and placebo + 10 mg piperine were used for the control
168 groups. Two treatment arms supplemented turmeric for the intervention, while the control group was

169 provided with cornstarch flour. A wide range of curcumin supplementation doses was utilized in the study
170 designs: curcumin capsules of 80 to 1500 mg/d and turmeric capsules of 2100 mg per day.
171 Supplementation duration varied from 8 to 28 weeks. Participant characteristics were also similar between
172 studies, focusing on specific patient populations, including type 2 diabetic patients (Table 2).

173 **Risk of bias**

174 We evaluated the quality of evidence using the Grading of Recommendations, Assessment, Development,
175 and Evaluation (GRADE) approach[29]. GRADE consists of a rating system where the quality of the
176 evidence for each outcome ranges from high to very low. The grade results are shown in Table 3. To sum
177 up, our results indicated a moderate effect of curcumin on body weight, a low effect on BMI, and a high
178 effect on WC.

Summary of findings

179

180 **The pooled estimate of curcumins on body weight, body mass index, and waist circumference** 181 **indices**

182 The results of forest plots are illustrated in Figure 2A–C. The body weight, BMI, and WC results were
183 reported using the random-effect model because statistically significant heterogeneity was observed
184 between these studies. Combined results from six studies (174 cases and 181 controls) indicated a
185 significant decrease in body weight after curcumin consumption (WMD: - 1.65 kg, 95% CI: -3.04, -0.27,
186 $p = 0.019$) with significant heterogeneity between the studies ($I^2 = 78.67\%$, $p = 0.000$) (Fig. 2A).

187 Pooled results from eight trials (242 cases and 244 controls) showed a significant decrease in BMI in
188 curcumin consumers compared with the control group (WMD: - 0.69 kg m², 95% CI: -0.99, -0.39, $p =$
189 0.000), with severe heterogeneity being detected ($I^2 = 92.48\%$, $p = 0.000$) (Fig. 2B).

190 Combined results of three studies (168 cases and 169 controls) revealed a significant reduction in WC
191 percent following curcumin consumption (WMD: - 0.93cm, 95% CI: -1.42, - 0.44, $p = 0.000$). There was
192 no significant heterogeneity between the studies ($I^2 = 25.65\%$, $p = 0.261$) (Fig. 2C).

193 **Sensitivity analysis**

194 To observe the impact of each single study on the pooled effect size, we conducted a leave-one-out
195 sensitivity analysis (Figs. 1A-C). The estimated effect size for curcumin's effect on BMI and WC was
196 robust, suggesting that removing each trial did not change the analysis results. However, by removing
197 studies of Mahsa Ahmadi Darmian [10] (WMD: -1.04 kg, 95% CI: -2.25, 0.16, $p = 0.089$) and Yunes
198 Panahi [26], (WMD: -1.59 kg, 95% CI: -3.04, 0.23, $p = 0.088$), the effect on body weight was no longer
199 statistically significant.

200 **Subgroup analysis**

201 The subgroup analyses were conducted (Table 4) to explore the effect of curcumin dose and duration on
202 the overall impact of curcumin on the estimated effect size. When the studies were stratified according to

203 the dose of curcumin consumed, as a high dose ($> 1000\text{mg/day}$) or a low dose ($\leq 1000\text{ mg/day}$),
204 significant reductions in body weight were observed in the subsets of studies with $> 1000\text{ mg/day}$ of
205 curcumin consumption (WMD: $- 4.59\text{ kg}$, 95% CI: $-6.92, -2.25$, $p = 0.002$) but not in those with ≤ 1000
206 g/day (WMD: $- 0.93\text{ kg}$, 95% CI: $-2.24, 0.37$, $p = 0.164$). Also, curcumin significantly reduced BMI in
207 doses $> 1000\text{ mg/day}$ (WMD: -0.99 , 95% CI: $-1.63, -0.35$, $p < 0.002$). This effect has also been seen in
208 doses $\leq 1000\text{ mg/day}$ (WMD: -0.21 , 95% CI: $-0.49, 0.05$, $p < 0.011$). The reduction in WC was observed
209 both after consuming $> 1000\text{ mg/day}$ of curcumin dose (WMD: -0.77 cm , 95% CI: $- 0.94, -0.60$, $p =$
210 0.000) and lower doses (WMD: -1.04 kg , 95% CI $-2.30, -0.49$, $p = 0.002$). However, it seems that the
211 reduction in the higher doses was more than the lower doses. Subgroup analysis was also performed by
212 dividing the duration of curcumin intervention (≥ 10 weeks vs. < 10 weeks). Subgroup analysis indicated
213 that curcumin consumption does not have a significant effect on reducing body weight (WMD: -1.51 kg ,
214 95% CI: $-3.09, 0.07$, $p = 0.06$), BMI (WMD: -0.61 , 95% CI: $-1.03, -0.19$, $p < 0.004$) and WC (WMD: $-$
215 2.70 , 95% CI: $6.65, 1.25$, $p = 0.18$) in longer-term interventions.

216 **Meta-regression**

217 A significant association was found between changes in body weight and the dose of supplementation,
218 but not with BMI (Fig. S2 panel A-B) and Table 3). Considering the duration of supplementation with
219 curcumin, no significant association was found.

220 **Publication bias**

221 Based on Egger's regression test, there was no evidence of publication bias for studies examining the
222 effect of curcumin on body weight ($p = 0.370$), BMI ($p = 0.071$), and WC ($p = 0.164$). Furthermore, based
223 on Begg's rank correlation tests, there was no significant publication bias for studies on body weight ($p =$
224 1.000), BMI ($p = 0.386$), and WC ($p = 1.000$). Funnel plots of the impact of curcumin on body weight,
225 BMI, and WC are illustrated in (Fig. S3A-C). Additionally, 32,827 and 43 studies would be required to
226 bring the effect size of body weight, BMI, and WC, respectively, to a non-significant ($p > 0.05$) value in
227 the analysis of the "fail-safe N" test.

228 **Discussion**

229 Limited systematic reviews and meta-analyses have been conducted on the effects of curcumin
230 supplementation on body weight, body mass index, and waist circumference. However, the current
231 systematic review and meta-analysis are the first studies that independently evaluate the effect of
232 curcumin supplementation on BW, WC, and BMI from existing RCTs in diabetic patients. A meta-
233 analysis of data from nine RCTs shows a significant effect of curcumin supplementation on BW, BMI,
234 and WC. However, a significant reduction in BW and BMI was observed, especially at doses higher than
235 1000 mg/day in some trials.

236 Data obtained from this systematic review and meta-analysis examined curcumin supplementation's
237 effects on body composition indices, including in adults. In line with our study, Mousavi et al.'s results
238 showed that curcumin supplementation significantly reduced BW and BMI compared to the control
239 group, and unlike our study, no significant effect of curcumin on WC[12]. The findings of a similar
240 systematic review and meta-analysis done by Akbari and Chanita Unhapitpong demonstrated that
241 curcumin consumption leads to a significantly reduced BW, BMI, and WC, which aligns with the results
242 of our study. However, the reducing effect of curcumin on BW and BMI in our study is more than in
243 those two studies. The effect of curcumin on waist circumference (WC) in our study was found to be
244 greater than that reported by Akbari et al., likely because the participants in our study[30, 31] had similar
245 health conditions. In addition, a systematic review of clinical trials found that curcumin supplementation
246 may reduce obesity and overweight in adults[32]. However, curcumin supplementation did not change
247 BW and BMI in obese adults compared to placebo in a clinical trial[33]. Also, curcumin did not
248 significantly affect BW in patients with metabolic syndrome[17]. Several meta-analyses and clinical trials
249 were conducted, but no significant effect of curcumin on WC[12, 18, 33-35].

250 Nevertheless, findings from another clinical trial investigating the effect of supplementation with
251 curcumin (1000mg/day) on patients with non-alcoholic fatty liver disease (NAFLD) for 8 weeks showed a
252 significant reduction in WC compared to the supplementation to placebo[36]. It should be noted that,
253 unlike BW and BMI, WC is considered a good indicator of abdominal and general obesity[37]. Due to
254 few available studies on the effect of curcumin supplementation on WC and their conflicting results on
255 the effect of curcumin supplementation on BW, BMI, and WC, further studies are required to reach a firm
256 conclusion in this area[38].

257 The subgroup analysis reveals some differences, such as significant reductions in BW observed in the
258 subsets of studies with > 1000 mg/day dose of curcumin consumption ($p = 0.002$) but not in those with \leq
259 1000 g/day ($p = 0.164$). Also, curcumin had a significant effect in reducing BMI in doses > 1000 mg/day
260 ($p < 0.002$); this effect has also been seen in doses ≤ 1000 mg/day ($p < 0.011$). The reduction in WC was
261 observed both after consuming doses > 1000 mg/day of curcumin ($p = 0.000$) and lower doses ($p =$
262 0.002). However, it seems that the reduction in the higher dose was more significant than the lower dose.
263 These findings indicate that higher doses of curcumin have a greater effect on anthropometric indices in
264 diabetic patients.

265 Curcumin is the most important ingredient of turmeric (*curcuma longa*) and is yellow. Curcumin is comm
266 only used as a food additive in Asian countries [3[6]. This substance also has therapeutic properties. It is
267 an active ingredient of turmeric that has antioxidant and anti-inflammatory properties. Currently, the US
268 Food and Drug Administration (FDA) has approved curcumin as Generally Recognized as Safe
269 (GRAS)[28, 39], and the European Food Safety Authority (EFSA) has recommended an acceptable dose

270 of 3 mg/kg/d[40]. Several studies have shown that curcumin has an acceptable safety profile with minimal
271 side effects[41, 42]. Curcumin has been shown to have several therapeutic benefits for various diseases,
272 such as metabolic syndrome, type 2 diabetes, hyperlipidemia, and Alzheimer's disease[1, 3, 27, 43].
273 However, a major limitation of curcumin as an agent with an oral route of administration is its low
274 bioavailability due to its poor absorption in the gastrointestinal tract, rapid metabolism, and fast
275 elimination from systemic circulation[1, 44].

276 On the other hand, obesity is a global health problem and a major risk factor for type 2 diabetes. Our
277 meta-analysis shows the beneficial effects of curcumin supplementation in reducing BMI, BW, and waist
278 circumference, confirming the results of the latest studies[45].

279 The mechanisms by which curcumin affects body weight and BMI are unclear. Nonetheless, previous
280 studies suggest several mechanisms through which curcumin may play a role in weight loss. Curcumin
281 down-regulates Janus Kinase (JNK) enzyme, which has been suggested to have a fundamental role in
282 obesity pathogenesis[1, 46, 47]. Curcumin can also inhibit the 11 β HSD-1 enzyme that activates cortisol,
283 and higher cortisol concentrations in adipocytes induce central obesity[48]. In addition, curcumin
284 promotes fatty acid oxidation and increases adipocyte apoptosis. In addition, curcumin inhibits NF- κ B in
285 adipose tissue, resulting in a reduced level of inflammatory cytokines, for example, tumor necrosis factor
286 α (TNF α), IL-1, IL-6, monocyte chemotactic protein 1, and plasminogen activator inhibitor type 1.
287 Curcumin has also been revealed to increase adiponectin levels[6, 13, 27]. It reduces obesity by inhibiting
288 adipocyte differentiation in the early stages through the suppression of the transcription factor
289 Proliferator-Activated Receptor-c (PPAR-c) and by activating adenosine monophosphate-activated
290 protein kinase (AMPK), which in turn enhances lipolysis[3, 26].

291 Finally, the dysbiosis of the intestinal microbiota is also one of the pathogens of obesity, and curcumin
292 acts as a prebiotic, distributing in the intestines and influencing the composition and diversity of the
293 microbiota. However, the effect of curcumin on obesity via gut microbiota homeostasis is still
294 controversial[26, 49, 50]. This study showed that curcumin supplementation can reduce body weight,
295 BMI, and WC in patients with type 2 diabetes, which can effectively reduce insulin sensitivity in type 2
296 diabetes patients.

297 **limitations and strengths**

298 Our systematic review has several limitations. Firstly, most of the included RCTs were performed in Iran.
299 Therefore, differences in daily curcumin intake and lifestyle may be underestimated. Secondly, curcumin
300 may have different effects on males and females because of its different fat content, but there was just one
301 article that focused solely on females and no articles on males. Clinical trials are necessary to assess
302 curcumin's effects on anthropometric variables separately in males and females. Third, the treatment

303 duration in most articles was short. Only two articles reported a study that followed participants for over
304 12 weeks. Fourth, the significant heterogeneity among studies shows that the effects of curcumin on BW,
305 BMI, and WC should be further investigated. The fifth, the removal of an individual study or a group of
306 studies, as assessed by sensitivity analysis, did not have a significant effect on BMI and WC results.
307 However, the removal of two studies related to BW had a significant effect on the findings. Finally, the
308 number of studies related to WC was less than the appropriate number to perform the regression test, so
309 the regression test was not performed on this index.

310 It should be noted that this study was not registered with Prospero. This systematic review has some
311 strength. To the best of our knowledge, this study is the first meta-analysis that independently evaluates
312 the effect of curcumin supplementation on BW, WC, and BMI in diabetic patients. No evidence of
313 publication bias was seen in this meta-analysis, as examined by the Egger and Begg regression test; in our
314 systematic review, curcumin dose ranged from low to high; therefore, the effects of dose were considered
315 in this systematic review. Also, the included studies were of moderate and high methodological quality.
316 They were done on participants with the same disease. Besides, based on RAB1 quality assessment
317 guidelines, most studies were of moderate and high quality. In addition, we could find sources of
318 between-study heterogeneity in our subgroup analyses.

319 **Conclusion**

320 In our meta-analysis, sufficient evidence was found regarding curcumin's significant effect on BW, BMI,
321 and WC. However, more evident doses higher than 1000 mg/day are required. Therefore, additional high-
322 quality, well-designed studies should be performed to approve our findings.

323 **Declaration**

324 **Funding**

325 This study received no grants from commercial, public, or nonprofit entities.

326 **Competing interests**

327 The authors declare that they have no competing interests.

328 **Data availability statements**

329 All data obtained from this research are included in the article's main text.

330 **Author contributions**

331 NAL, SF, and EA conceived the study. NAL carried out the literature search and wrote the manuscript.
332 NAL and SAL carried out data extraction and independent reviewing. NAL, EA, and SF assessed the
333 quality of the included studies. NAL and SF performed data analysis and interpretation, and SJM revised
334 the manuscript. The manuscript has been read and approved by all authors.

335 **Ethical approval and consent to participate**

336 Not applicable.

337 **Consent to participate**

338 Not applicable.

339 **Consent to publication**

340 The author fully consents to the publication of the article.

341

342 **References**

- 343 1. Rahimi, H.R., et al., *The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid*
344 *profile in diabetic subjects: a randomized clinical trial*. Avicenna journal of phytomedicine,
345 2016. **6**(5): p. 567.
- 346 2. Adab, Z., et al., *Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total*
347 *antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients*. Phytotherapy Research,
348 2019. **33**(4): p. 1173-1181.
- 349 3. Ebrahimkhani, S., S. Ghavamzadeh, and A. Mehdizadeh, *The effects of vitamin D and*
350 *curcuminoids supplementation on anthropometric measurements and blood pressure in type 2*
351 *diabetic patients with coexisting hypovitaminosis D: A double-blind, placebo-controlled*
352 *randomized clinical trial*. Clinical nutrition ESPEN, 2020. **37**: p. 178-186.
- 353 4. Ramsey, S.D., et al., *Varroa destructor feeds primarily on honey bee fat body tissue and not*
354 *hemolymph*. Proceedings of the National Academy of Sciences, 2019. **116**(5): p. 1792-1801.
- 355 5. Baziar, N. and M. Parohan, *The effects of curcumin supplementation on body mass index, body*
356 *weight, and waist circumference in patients with nonalcoholic fatty liver disease: a systematic*
357 *review and dose–response meta-analysis of randomized controlled trials*. Phytotherapy
358 Research, 2020. **34**(3): p. 464-474.
- 359 6. Hodaei, H., et al., *The effect of curcumin supplementation on anthropometric indices, insulin*
360 *resistance and oxidative stress in patients with type 2 diabetes: A randomized, double-blind*
361 *clinical trial*. Diabetology & metabolic syndrome, 2019. **11**: p. 1-8.
- 362 7. Verma, S. and M.E. Hussain, *Obesity and diabetes: an update*. Diabetes & Metabolic Syndrome:
363 Clinical Research & Reviews, 2017. **11**(1): p. 73-79.
- 364 8. Aucott, L.S., *Influences of weight loss on long-term diabetes outcomes: symposium on ‘diet and*
365 *diabetes’*. Proceedings of the Nutrition Society, 2008. **67**(1): p. 54-59.
- 366 9. Abbasi, E., *A review of cultural aspects and barriers to the consumption of edible insects*. Health
367 Science Monitor, 2024. **3**(3): p. 179-194.
- 368 10. Darmian, M.A., et al., *How combined and separate aerobic training and turmeric*
369 *supplementation alter lipid profile and glycemic status? A clinical trial in middle-aged females*

- 370 *with type 2 diabetes and hyperlipidemia*. International Cardiovascular Research Journal, 2021.
371 **15**(3).
- 372 11. Adab, Z., et al., *Effect of turmeric on body measurement indices, glycemic condition, and lipid*
373 *profile in hyperlipidemic patients with type 2 diabetes*. Iranian Journal of Nutrition Sciences and
374 Food Technology, 2013. **8**(3): p. 217-227.
- 375 12. Mousavi, S.M., et al., *The effects of curcumin supplementation on body weight, body mass index*
376 *and waist circumference: a systematic review and dose-response meta-analysis of randomized*
377 *controlled trials*. Critical reviews in food science and nutrition, 2020. **60**(1): p. 171-180.
- 378 13. Asadi, S., et al., *Nano curcumin supplementation reduced the severity of diabetic sensorimotor*
379 *polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo-*
380 *controlled clinical trial*. Complementary therapies in medicine, 2019. **43**: p. 253-260.
- 381 14. Navekar, R., et al., *Turmeric supplementation improves serum glucose indices and leptin levels in*
382 *patients with nonalcoholic fatty liver diseases*. Journal of the American College of Nutrition,
383 2017. **36**(4): p. 261-267.
- 384 15. Panahi, Y., et al., *Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a*
385 *clinical study*. Journal of Asian natural products research, 2018.
- 386 16. Rahmani, S., et al., *Treatment of non-alcoholic fatty liver disease with curcumin: A randomized*
387 *placebo-controlled trial*. Phytotherapy Research, 2016. **30**(9): p. 1540-1548.
- 388 17. Yang, Y.S., et al., *Lipid-lowering effects of curcumin in patients with metabolic syndrome: a*
389 *randomized, double-blind, placebo-controlled trial*. Phytotherapy research, 2014. **28**(12): p.
390 1770-1777.
- 391 18. Campbell, M.S., et al., *Responsiveness to curcumin intervention is associated with reduced aortic*
392 *stiffness in young, obese men with higher initial stiffness*. Journal of Functional Foods, 2017. **29**:
393 p. 154-160.
- 394 19. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting systematic*
395 *reviews*. Bmj, 2021. **372**.
- 396 20. Higgins, J.P., et al., *The Cochrane Collaboration's tool for assessing risk of bias in randomised*
397 *trials*. Bmj, 2011. **343**.
- 398 21. Borenstein, M. and H. Rothstein, *Comprehensive meta-analysis*. 1999: Biostat.
- 399 22. Reeves, B.C., et al., *Including non-randomized studies*. Cochrane handbook for systematic
400 reviews of interventions: Cochrane book series, 2008: p. 389-432.
- 401 23. Hozo, S.P., B. Djulbegovic, and I. Hozo, *Estimating the mean and variance from the median,*
402 *range, and the size of a sample*. BMC medical research methodology, 2005. **5**: p. 1-10.

- 403 24. Sahebkar, A., *Are curcuminoids effective C-reactive protein-lowering agents in clinical*
404 *practice? Evidence from a meta-analysis*. *Phytotherapy research*, 2014. **28**(5): p. 633-642.
- 405 25. Duval, S. and R. Tweedie, *Trim and fill: a simple funnel-plot-based method of testing and*
406 *adjusting for publication bias in meta-analysis*. *Biometrics*, 2000. **56**(2): p. 455-463.
- 407 26. Panahi, Y., et al., *Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory*
408 *biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-*
409 *controlled trial*. *Drug research*, 2018. **68**(07): p. 403-409.
- 410 27. Chuengsamarn, S., et al., *Reduction of atherogenic risk in patients with type 2 diabetes by*
411 *curcuminoid extract: a randomized controlled trial*. *The Journal of nutritional biochemistry*,
412 2014. **25**(2): p. 144-150.
- 413 28. Neta, J.F.d.F., et al., *Effectiveness of the piperine-supplemented Curcuma longa L. in metabolic*
414 *control of patients with type 2 diabetes: a randomised double-blind placebo-controlled clinical*
415 *trial*. *International journal of food sciences and nutrition*, 2021. **72**(7): p. 968-977.
- 416 29. Guyatt, G.H., et al., *GRADE guidelines: a new series of articles in the Journal of Clinical*
417 *Epidemiology*. *Journal of clinical epidemiology*, 2011. **64**(4): p. 380-382.
- 418 30. Chanita Unhapipatpong, M., *The Effect of Curcumin Supplementation on Weight Loss and*
419 *Anthropometric Indices: An Umbrella Review and Updated Meta-analyses of Randomized*
420 *Controlled Trials*. Department of Clinical Epidemiology and Biostatistics, Faculty of
421 Medicine
- 422 31. Akbari, M., et al., *The effects of curcumin on weight loss among patients with metabolic*
423 *syndrome and related disorders: a systematic review and meta-analysis of randomized controlled*
424 *trials*. *Front Pharmacol* **10**: 649. 2019.
- 425 32. Hariri, M. and F. Haghghatdoost, *Effect of curcumin on anthropometric measures: a systematic*
426 *review on randomized clinical trials*. *Journal of the American College of Nutrition*, 2018. **37**(3):
427 p. 215-222.
- 428 33. Mohammadi, A., et al., *Effects of supplementation with curcuminoids on dyslipidemia in obese*
429 *patients: a randomized crossover trial*. *Phytotherapy Research*, 2013. **27**(3): p. 374-379.
- 430 34. Mohammadi, A., et al., *Effects of curcumin on serum vitamin E concentrations in individuals with*
431 *metabolic syndrome*. *Phytotherapy research*, 2017. **31**(4): p. 657-662.
- 432 35. Di Pierro, F., et al., *Potential role of bioavailable curcumin in weight loss and omental adipose*
433 *tissue decrease: preliminary data of a randomized, controlled trial in overweight people with*
434 *metabolic syndrome. Preliminary study*. *European Review for Medical & Pharmacological*
435 *Sciences*, 2015. **19**(21).

- 436 36. Panahi, Y., et al., *Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial*. Drug research, 2017. **67**(04): p. 244-251.
- 437
- 438 37. Gearon, E., et al., *Changes in waist circumference independent of weight: Implications for population level monitoring of obesity*. Preventive medicine, 2018. **111**: p. 378-383.
- 439
- 440 38. Jalali, M., et al., *The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials*. Complementary therapies in medicine, 2020. **48**: p. 102283.
- 441
- 442
- 443
- 444 39. Bethesda, M., *Drugs and lactation database (LactMed)*. National Library of Medicine (US): Bethesda, MD, USA, 2006.
- 445
- 446 40. Additives, E.P.o.F. and N.S.a.t. Food, *Scientific opinion on the re-evaluation of curcumin (E 100) as a food additive*. EFSA journal, 2010. **8**(9): p. 1679.
- 447
- 448 41. Hewlings, S.J. and D.S. Kalman, *Curcumin: A review of its effects on human health*. Foods, 2017. **6**(10): p. 92.
- 449
- 450 42. Lao, C.D., et al., *Dose escalation of a curcuminoid formulation*. BMC complementary and alternative medicine, 2006. **6**(1): p. 10.
- 451
- 452 43. Masella, R. and F. Cirulli, *Curcumin: a promising tool to develop preventive and therapeutic strategies against non-communicable diseases, still requiring verification by sound clinical trials*. 2022, MDPI. p. 1401.
- 453
- 454
- 455 44. Gopinath, H. and K. Karthikeyan, *Turmeric: A condiment, cosmetic and cure*. Indian journal of dermatology, venereology and leprology, 2018. **84**: p. 16.
- 456
- 457 45. Sun, Z., et al., *The effects of curcumin on anthropometric and cardiometabolic parameters of patients with metabolic related diseases: a systematic review and dose-effect meta-analysis of randomized controlled trials*. Critical reviews in food science and nutrition, 2023. **63**(28): p. 9282-9298.
- 458
- 459
- 460
- 461 46. Panahi, Y., et al., *Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus*. Current clinical pharmacology, 2017. **12**(4): p. 253-258.
- 462
- 463 47. Alidadi, M., et al., *The effect of curcumin supplementation on pulse wave velocity in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial*. Pharmacological properties of plant-derived natural products and implications for human health, 2021: p. 1-11.
- 464
- 465
- 466 48. Akbari, M., et al., *The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials*. Frontiers in pharmacology, 2019. **10**: p. 439144.
- 467
- 468

- 469 49. Vamanu, E. and S.N. Rai, *The link between obesity, microbiota dysbiosis, and neurodegenerative*
470 *pathogenesis*. Diseases, 2021. **9**(3): p. 45.
- 471 50. Kasprzak-Droz, K., et al., *Curcumin and weight loss: does it work?* International journal of
472 molecular sciences, 2022. **23**(2): p. 639.

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488


489

490

491

492

493



494

495

496

497


498

499

500

Fig 1. The review process based on PRISMA flow chart

body weight



501

502 Figure 2A. The body weight, BMI, and WC results were reported using the random-effect model.

503

504

505

506

507

508


509

510

511

512

Body mass index(BMI)



513

514 Fig 2B. Pooled results from eight trials showed a significant decrease in BMI in curcumin consumers
 515 compared with the control group.

516

517

518

519

520


521

522

523

524

Waist Circumference(WC)



525

526 Fig 2C. Combined results of three studies revealed a significant reduction in WC percent following
527 curcumin consumption.

528

529

530

531

532

533

534

535

Table 1. Main characteristics of the included studies.

First author (publication year)	Country	Sample size (M/F, Intervention/Control)	Target population	Mean age (yr)	BMI (kg/m ²)	Study design (randomization, blinding)	Intervention group	Control group	Dose (mg/d)	Duration (w)	Results
Hamid Reza Rahimi (2015)	Iran	70 (31/39, 35/35)	T2DM	56.3	-	Parallel (yes, double)	Curcumin	placebo	80	12	↓ BMI
Homa Hodaei (2019)	Iran	44 (22/22, 21/23)	T2DM	58	18.5-35	Parallel (yes, double)	Curcumin capsules	cooked rice	1500	10	↓ BW, ↓ BMI, ↓ WC,
Joana Furtado de Figueiredo Neta, (2021)	Brazil	61 (14/47, 33/28)	T2DM	62.5	-	Parallel (yes, double)	curcumin capsules plus 5mg piperine	Placebo capsules	500	17	↓ BMI,
Mahsa Ahmadi Darmian (2021)	Iran	21 (0/21, 11/10)	T2DM	44.3	25-30	Parallel (yes, single)	turmeric capsules	Corn starch flour capsules	2100	8	↓ BW, ↓ BMI,
Sara Asadia (2019)	Iran	80 (10/70, 40/40)	T2DM	53.3	25-39.9	Parallel (yes, double)	curcumin capsules	Polysorbate capsules	80	8	↓ BW, ↓ BMI, ↓ WC
Shirin Ebrahimkhani (2020)	Iran	35 (13/22, 16/19)	T2DM	56.1	-	Parallel (yes, double)	curcumin	maltodextrin	500	12	↔, BW, ↔, BMI,
Somlak Chuengsamarn (2014)	Thailand	213 (/97,116 107/106)	T2DM	59.1	-	Parallel (yes, double)	curcumin capsules	placebo capsule contains starch	1500	25	↓ WC,
Yunes Panahi (2017)	Iran	100 (51/49, 50/50)	T2DM	43	-	Parallel (yes, double)	curcumin plus 10 mg piperine	PLASEBO+ 10MG PIPERINE	1000	12	↓ BW, ↓ BMI,
Zohreh Adab (2018)	Iran	75 (36/39, 36/39)	T2DM	54.7	-	parallel (yes, double)	turmeric supplement	corn starch flour	2100	8	↓ BW, ↓ BMI,

Symbols: ↓, significant decrease; ↑, significant increase; ↔, no significant difference.

Abbreviations: BW; body wight, BMI, body mass index; WC, waist circumference

Table2 *Quality assessment of clinical trials (according to Cochrane guideline)* The effects of curcumin supplementation on body weight, body mass index and waist circumference in patients with type 2 diabetes.

Study	Random Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	incomplete outcome data	Selective outcome reporting	Other potential sources of biases	General Risk of Bias
Hamid Reza Rahimi (2015)	L	H	L	U	L	H	L	Moderate
Homa Hodaiei (2019)	L	U	L	L	L	L	L	Low
Joana Furtado de Figueiredo Neta, (2021)	U	H	L	H	L	H	H	High
Mahsa Ahmadi Darmian (2021)	L	H	H	H	L	H	H	High
Sara Asadia (2019)	L	H	L	U	L	L	L	Low
Shirin Ebrahimkhani (2020)	L	U	L	U	L	H	L	Low
Somlak Chuengsamarn (2014)	L	L	L	U	L	H	L	Low
Yunes Panahi (2017)	H	H	L	H	L	H	H	High
Zohreh Adab (2018)	L	H	L	U	L	H	L	Moderate

H: High, M: Moderate, L: Low

Table 3 Grade profile of Curcumin supplementation on Body weight, BMI and WC

Outcomes	Quality assessment					Summary of findings		
	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Number of intervention/control	WMD, 95% CI	Quality of evidence
<i>Body weight</i>	NO Serious limitation	Serious limitation	NO Serious limitation	NO Serious limitation	NO Serious limitation	174/181	-1.65(-3.04, -0.27)	moderate
<i>BMI</i>	NO Serious limitation	Very Serious limitation	NO Serious limitation	NO Serious limitation	NO Serious limitation	242/244	-0.69(-0.99, -0.39)	Low
<i>WC</i>	NO Serious limitation	NO Serious limitation	NO Serious limitation	NO Serious limitation	NO Serious limitation	168/169	-0.93(-1.42, -0.44)	High

Table 4 Results of subgroup analysis of included randomized controlled trials in the meta-analysis of curcumin supplementation and Body wight, BMI and WC - related parameters.

Variables	Dose (mg/day)		Duration (weeks)	
	>1000	≤1000	≥10 weeks	<10 weeks
Body wigt (Kg)				
Number of Comparisons	3	3	3	3
WMD (95% CI)	- 4.59 (-6.92, -2.25)	- 0.93 (-2.24, 0.37)	-1.24 (-2.98, 0.49)	-2.83 (-6.68, 1.00)
p value	0.002	0.164	0.161	0.148
I2 (%)	0.605	84.63	62.38	84.28
P heterogeneity	0.000	0.001	0.070	0.002
BMI (kg/m2)				
Number of Comparisons	4	4	4	4
WMD (95% CI)	-0.99 (-1.63, -0.35)	-0.21 (-0.49, 0.05)	-0.61 (-1.03, -0.19)	-0.73 (-1.10, -0.36)
p value	<0.002	<0.011	<0.004	0.000
I2 (%)	96.64	16.27	33.76	95.85
P heterogeneity	0.000	0.310	0.210	0.000
WC (cm)				
Number of Comparisons	2	1	1	2
WMD (95% CI)	-0.77 (- 0.94, -0.60)	-1.04 (-2.30, -0.49)	-2.07 (-6.65, -1.25)	-0.92 (-1.45, -0.39)
p value	0.000	0.002	0.181	0.001
I2 (%)	0.000	0.000	0.000	44.37
P heterogeneity	0.340	1.000	1.000	0.180

Table 5 Meta-regression between changes in Body Weight and was found with changes in Body wight and BMI (Fig. 5 panel A-B and Table 3).

<i>model</i>	<i>Random effect</i>		
	Slope	95%CI	P value
Body wight			
Dose of supplementation	-0.0020	-0.002 to -0.001	0.000
Intervention duration	0.3467	-0.630 to 1.324	0.486
BMI			
Dose of supplementation	-0.0005	-0.0011 to 0.0001	0.096
Intervention duration	0.94	-0.085 to 0.275	0.303

BMI and administered doses and intervention duration of curcumin

Table 6 Assessment of publication bias in the impact of curcumin on Body wight, Body mass index and Waist circumference in patients with type 2 diabetes

	Corrected effect size	Begg's rank correlation			Egger's linear regression test				Fail-safe N Test	
	WMD 95% CI	Kendall's tau	z value	p value	Intercept	95% C	t value	df	p value	n
Body wight	-1.65 (-3.04, -0.27)	0.000	0.000	1.000	-1.38	(-5.18,2.48)	1.007	4.0	0.370	32
BMI	-0.69 (-0.99, -0.39)	-0.25	0.86	0.386	-2.52	(-.5.34,0.30)	2.183	6.0	0.071	82
WC	-0.93 (-1.42,0.44)	0.000	0.000	1.000	-1.27	(-5.56,3.01)	3.78	1.0	0.164	43

Abbreviations: BMI, body mass index; WC, waist circumference; WMD, weight mean difference.